Science 30 April 1976: Vol. 192. no. 4238, pp. 481 - 483 DOI: 10.1126/science.3854

Prev | Table of Contents | Next

Articles

Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs--An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature.

J. M. Stone, J. M. Davis, S. Leucht, and L. S. Pilowsky (2009)
Schizophr Bull 35, 789-797
 |  Abstract »  |  Full Text »  |  PDF »

Presynaptic Regulation of Dopamine Transmission in Schizophrenia.

G. J. Lyon, A. Abi-Dargham, H. Moore, J. A. Lieberman, J. A. Javitch, and D. Sulzer (2009)
Schizophr Bull
 |  Abstract »  |  Full Text »  |  PDF »

The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway.

O. D. Howes and S. Kapur (2009)
Schizophr Bull 35, 549-562
 |  Abstract »  |  Full Text »  |  PDF »

What We Know: Findings That Every Theory of Schizophrenia Should Explain.

A. W. MacDonald and S. C. Schulz (2009)
Schizophr Bull 35, 493-508
 |  Abstract »  |  Full Text »  |  PDF »

Drug Discovery in Psychiatric Illness: Mining for Gold.

G. I. Elmer and N. Kafkafi (2009)
Schizophr Bull
 |  Abstract »  |  Full Text »  |  PDF »

Antagonism of dopamine D2 receptor/{beta}-arrestin 2 interaction is a common property of clinically effective antipsychotics.

B. Masri, A. Salahpour, M. Didriksen, V. Ghisi, J.-M. Beaulieu, R. R. Gainetdinov, and M. G. Caron (2008)
PNAS 105, 13656-13661
 |  Abstract »  |  Full Text »  |  PDF »

Messing Up with Traffic: Different Effects of Antipsychotic Agents on Glutamate Receptor Complexes in Vivo.

T. Del'guidice and J.-M. Beaulieu (2008)
Mol. Pharmacol. 73, 1339-1342
 |  Abstract »  |  Full Text »  |  PDF »

Quetiapine: Treatment for substance abuse and drug of abuse.

M. J. Hanley and G. A. Kenna (2008)
Am. J. Health Syst. Pharm. 65, 611-618
 |  Abstract »  |  Full Text »  |  PDF »

A network of dopaminergic gene variations implicated as risk factors for schizophrenia.

M. E. Talkowski, G. Kirov, M. Bamne, L. Georgieva, G. Torres, H. Mansour, K. V. Chowdari, V. Milanova, J. Wood, L. McClain, et al. (2008)
Hum. Mol. Genet. 17, 747-758
 |  Abstract »  |  Full Text »  |  PDF »

Ether-a-go-go Related Gene Potassium Channels: What's All the Buzz About?.

P. D. Shepard, C. C. Canavier, and E. S. Levitan (2007)
Schizophr Bull 33, 1263-1269
 |  Abstract »  |  Full Text »  |  PDF »

Dopamine Genes and Schizophrenia: Case Closed or Evidence Pending?.

M. E. Talkowski, M. Bamne, H. Mansour, and V. L. Nimgaonkar (2007)
Schizophr Bull 33, 1071-1081
 |  Abstract »  |  Full Text »  |  PDF »

Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions.

P.R. Corlett, G.K. Murray, G.D. Honey, M.R.F. Aitken, D.R. Shanks, T.W. Robbins, E.T. Bullmore, A. Dickinson, and P.C. Fletcher (2007)
Brain 130, 2387-2400
 |  Abstract »  |  Full Text »  |  PDF »

ACP-103, a 5-Hydroxytryptamine 2A Receptor Inverse Agonist, Improves the Antipsychotic Efficacy and Side-Effect Profile of Haloperidol and Risperidone in Experimental Models.

L. R. Gardell, K. E. Vanover, L. Pounds, R. W. Johnson, R. Barido, G. T. Anderson, I. Veinbergs, A. Dyssegaard, P. Brunmark, A. Tabatabaei, et al. (2007)
J. Pharmacol. Exp. Ther. 322, 862-870
 |  Abstract »  |  Full Text »  |  PDF »

Role of a G{alpha}i2 protein splice variant in the formation of an intracellular dopamine D2 receptor pool.

M. F. Lopez-Aranda, M. J. Acevedo, A. Gutierrez, P. Koulen, and Z. U. Khan (2007)
J. Cell Sci. 120, 2171-2178
 |  Abstract »  |  Full Text »  |  PDF »

From prediction error to psychosis: ketamine as a pharmacological model of delusions.

P.R. Corlett, G.D. Honey, and P.C. Fletcher (2007)
J Psychopharmacol 21, 238-252
 |  Abstract »  |  PDF »

Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?.

C. H. Large (2007)
J Psychopharmacol 21, 283-301
 |  Abstract »  |  PDF »

Effects of Toxoplasma on Human Behavior.

J. Flegr (2007)
Schizophr Bull 33, 757-760
 |  Abstract »  |  Full Text »  |  PDF »

RGS4 Modulates Serotonin Signaling in Prefrontal Cortex and Links to Serotonin Dysfunction in a Rat Model of Schizophrenia.

Z. Gu, Q. Jiang, and Z. Yan (2007)
Mol. Pharmacol. 71, 1030-1039
 |  Abstract »  |  Full Text »  |  PDF »

Dopaminergic Control of Sleep-Wake States.

K. Dzirasa, S. Ribeiro, R. Costa, L. M. Santos, S.-C. Lin, A. Grosmark, T. D. Sotnikova, R. R. Gainetdinov, M. G. Caron, and M. A. L. Nicolelis (2006)
J. Neurosci. 26, 10577-10589
 |  Abstract »  |  Full Text »  |  PDF »

New Models of Frontal-Subcortical Skeletomotor Circuit Pathology in Tardive Dyskinesia.

W. R. Marchand and V. Dilda (2006)
Neuroscientist 12, 186-198
 |  Abstract »  |  PDF »

Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist.

E. S. Burstein, J. Ma, S. Wong, Y. Gao, E. Pham, A. E. Knapp, N. R. Nash, R. Olsson, R. E. Davis, U. Hacksell, et al. (2005)
J. Pharmacol. Exp. Ther. 315, 1278-1287
 |  Abstract »  |  Full Text »  |  PDF »

Involvement of 5-HT1A Receptors in Prefrontal Cortex in the Modulation of Dopaminergic Activity: Role in Atypical Antipsychotic Action.

L. Diaz-Mataix, M. C. Scorza, A. Bortolozzi, M. Toth, P. Celada, and F. Artigas (2005)
J. Neurosci. 25, 10831-10843
 |  Abstract »  |  Full Text »  |  PDF »

The Choice of Antipsychotic Drugs for Schizophrenia.

R. Freedman (2005)
N. Engl. J. Med. 353, 1286-1288
 |  Full Text »  |  PDF »

Rational pharmacotherapy in early psychosis.

G. REMINGTON (2005)
The British Journal of Psychiatry 187, s77-s84
 |  Abstract »  |  Full Text »  |  PDF »

Partial agonism and schizophrenia.

A. A. Bolonna and R. W. Kerwin (2005)
The British Journal of Psychiatry 186, 7-10
 |  Full Text »  |  PDF »

Certain 1,4-Disubstituted Aromatic Piperidines and Piperazines with Extreme Selectivity for the Dopamine D4 Receptor Interact with a Common Receptor Microdomain.

S. Kortagere, P. Gmeiner, H. Weinstein, and J. A. Schetz (2004)
Mol. Pharmacol. 66, 1491-1499
 |  Abstract »  |  Full Text »  |  PDF »

Chronic Haloperidol Promotes Corticostriatal Long-Term Potentiation by Targeting Dopamine D2L Receptors.

D. Centonze, A. Usiello, C. Costa, B. Picconi, E. Erbs, G. Bernardi, E. Borrelli, and P. Calabresi (2004)
J. Neurosci. 24, 8214-8222
 |  Abstract »  |  Full Text »  |  PDF »

Pharmacogenetics of Psychotropic Drug Response.

A. K. Malhotra, G. M. Murphy Jr., and J. L. Kennedy (2004)
Am J Psychiatry 161, 780-796
 |  Abstract »  |  Full Text »  |  PDF »

The Neurobiology of Dopamine Signaling.

J.-A. Girault and P. Greengard (2004)
Arch Neurol 61, 641-644
 |  Abstract »  |  Full Text »  |  PDF »

D2 receptor regulation of synaptic burst firing in prefrontal cortical pyramidal neurons.

Y. Wang and P. S. Goldman-Rakic (2004)
PNAS 101, 5093-5098
 |  Abstract »  |  Full Text »  |  PDF »

Selective D2 Receptor Actions on the Functional Circuitry of Working Memory.

M. Wang, S. Vijayraghavan, and P. S. Goldman-Rakic (2004)
Science 303, 853-856
 |  Abstract »  |  Full Text »  |  PDF »

Atypical Antipsychotics: Mechanism of Action.

P. Seeman (2004)
Focus 2, 48-58
 |  Abstract »  |  Full Text »  |  PDF »

Potential for antipsychotic and psychotomimetic effects of A2A receptor modulation.

S. M. Weiss, E. Whawell, R. Upton, and C. T. Dourish (2003)
Neurology 61, S88-93
 |  Abstract »  |  Full Text »

Delayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected.

O. Agid, S. Kapur, T. Arenovich, and R. B. Zipursky (2003)
Arch Gen Psychiatry 60, 1228-1235
 |  Abstract »  |  Full Text »  |  PDF »

Long-Term K+ Channel-Mediated Dampening of Dopamine Neuron Excitability by the Antipsychotic Drug Haloperidol.

J. Hahn, T. E. Tse, and E. S. Levitan (2003)
J. Neurosci. 23, 10859-10866
 |  Abstract »  |  Full Text »  |  PDF »

Schizophrenia.

R. Freedman (2003)
N. Engl. J. Med. 349, 1738-1749
 |  Full Text »  |  PDF »

Regulation of NMDA Receptors by Dopamine D4 Signaling in Prefrontal Cortex.

X. Wang, P. Zhong, Z. Gu, and Z. Yan (2003)
J. Neurosci. 23, 9852-9861
 |  Abstract »  |  Full Text »  |  PDF »

Possible Roles of Kainate Receptors on GABAergic Nerve Terminals Projecting to Rat Substantia Nigra Dopaminergic Neurons.

M. Nakamura, I.-S. Jang, H. Ishibashi, S. Watanabe, and N. Akaike (2003)
J Neurophysiol 90, 1662-1670
 |  Abstract »  |  Full Text »  |  PDF »

The Extended Amygdala and the Dopamine System: Another Piece of the Dopamine Puzzle.

J. L. Fudge and A. B. Emiliano (2003)
J Neuropsychiatry Clin Neurosci 15, 306-316
 |  Abstract »  |  Full Text »

The Group II Metabotropic Glutamate Receptor Agonist (-)-2-Oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and Clozapine Reverse Phencyclidine-Induced Behaviors in Monoamine-Depleted Rats.

C. J. Swanson and D. D. Schoepp (2002)
J. Pharmacol. Exp. Ther. 303, 919-927
 |  Abstract »  |  Full Text »  |  PDF »

Forty Years of Neurotransmitters: A Personal Account.

S. H. Snyder (2002)
Arch Gen Psychiatry 59, 983-994
 |  Abstract »  |  Full Text »  |  PDF »

Dopamine and antipsychotic drug action revisited.

H. M. JONES and L. S. PILOWSKY (2002)
The British Journal of Psychiatry 181, 271-275
 |  Full Text »  |  PDF »

Evidence for Decreased DARPP-32 in the Prefrontal Cortex of Patients With Schizophrenia.

K. A. Albert, H. C. Hemmings Jr, A. I. B. Adamo, S. G. Potkin, S. Akbarian, C. A. Sandman, C. W. Cotman, W. E. Bunney Jr, and P. Greengard (2002)
Arch Gen Psychiatry 59, 705-712
 |  Abstract »  |  Full Text »  |  PDF »

Schizophrenia: Diverse Approaches to a Complex Disease.

A. Sawa and S. H. Snyder (2002)
Science 296, 692-695
 |  Abstract »  |  Full Text »  |  PDF »

Inverse Agonist Actions of Typical and Atypical Antipsychotic Drugs at the Human 5-Hydroxytryptamine2C Receptor.

L. Rauser, J. E. Savage, H. Y. Meltzer, and B. L. Roth (2001)
J. Pharmacol. Exp. Ther. 299, 83-89
 |  Abstract »  |  Full Text »  |  PDF »

5-Hydroxytryptamine2A Receptor Inverse Agonists as Antipsychotics.

D. M. Weiner, E. S. Burstein, N. Nash, G. E. Croston, E. A. Currier, K. E. Vanover, S. C. Harvey, E. Donohue, H. C. Hansen, C. M. Andersson, et al. (2001)
J. Pharmacol. Exp. Ther. 299, 268-276
 |  Abstract »  |  Full Text »  |  PDF »

Dosing Time-Dependent Tolerance of Catalepsy by Repetitive Administration of Haloperidol in Mice.

J. Viyoch, S. Ohdo, E. Yukawa, and S. Higuchi (2001)
J. Pharmacol. Exp. Ther. 298, 964-969
 |  Abstract »  |  Full Text »

No Support for Regional Selectivity in Clozapine-Treated Patients: A PET Study With [11C]Raclopride and [11C]FLB 457.

M. Talvik, A.-L. Nordstrom, S. Nyberg, H. Olsson, C. Halldin, and L. Farde (2001)
Am J Psychiatry 158, 926-930
 |  Abstract »  |  Full Text »  |  PDF »

Conventional and Atypical Antipsychotics and the Evolving Standard of Care.

D. Mossman and D. S. Lehrer (2000)
Psychiatr Serv 51, 1528-1535
 |  Abstract »  |  Full Text »  |  PDF »

Neurochemical Individuality: Genetic Diversity Among Human Dopamine and Serotonin Receptors and Transporters.

A. Cravchik and D. Goldman (2000)
Arch Gen Psychiatry 57, 1105-1114
 |  Abstract »  |  Full Text »  |  PDF »

Inverse Agonist Activity of Atypical Antipsychotic Drugs at Human 5-Hydroxytryptamine2C Receptors.

K. Herrick-Davis, E. Grinde, and M. Teitler (2000)
J. Pharmacol. Exp. Ther. 295, 226-232
 |  Abstract »  |  Full Text »

Phencyclidine Model of Frontal Cortical Dysfunction in Nonhuman Primates.

J. D. Jentsch, J. R. Taylor, and R. H. Roth (2000)
Neuroscientist 6, 263-270
 |  Abstract »  |  PDF »

From the Cover: Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

A. Abi-Dargham, J. Rodenhiser, D. Printz, Y. Zea-Ponce, R. Gil, L. S. Kegeles, R. Weiss, T. B. Cooper, J. J. Mann, R. L. Van Heertum, et al. (2000)
PNAS 97, 8104-8109
 |  Abstract »  |  Full Text »  |  PDF »

Inverse Agonist Properties of Dopaminergic Antagonists at the D1A Dopamine Receptor: Uncoupling of the D1A Dopamine Receptor from Gs Protein.

G. Cai, H. Gurdal, C. Smith, H.-Y. Wang, and E. Friedman (1999)
Mol. Pharmacol. 56, 989-996
 |  Abstract »  |  Full Text »

Muscarinic Receptor Agonists, Like Dopamine Receptor Antagonist Antipsychotics, Inhibit Conditioned Avoidance Response in Rats.

H. E. Shannon, J. C. Hart, F. P. Bymaster, D. O. Calligaro, N. W. DeLapp, C. H. Mitch, J. S. Ward, A. Fink-Jensen, P. Sauerberg, L. Jeppesen, et al. (1999)
J. Pharmacol. Exp. Ther. 290, 901-907
 |  Abstract »  |  Full Text »

Dopamine Modulation of Membrane and Synaptic Properties of Interneurons in Rat Cerebral Cortex.

F.-M. Zhou and J. J. Hablitz (1999)
J Neurophysiol 81, 967-976
 |  Abstract »  |  Full Text »  |  PDF »

Induction of NF-kappa B Activity during Haloperidol-Induced Oxidative Toxicity in Clonal Hippocampal Cells: Suppression of NF-kappa B and Neuroprotection by Antioxidants.

A. Post, F. Holsboer, and C. Behl (1998)
J. Neurosci. 18, 8236-8246
 |  Abstract »  |  Full Text »  |  PDF »

D2 Dopamine Antisense RNA Expression Vector, Unlike Haloperidol, Produces Long-term Inhibition of D2 Dopamine-Mediated Behaviors without Causing Up-regulation of D2 Dopamine Receptors.

G. Davidkova, L.-W. Zhou, M. Morabito, S.-P. Zhang, and B. Weiss (1998)
J. Pharmacol. Exp. Ther. 285, 1187-1196
 |  Abstract »  |  Full Text »

Monoaminergic synapses and schizophrenia: 45 years of neuroleptics.

M. R. Bennett (1998)
J Psychopharmacol 12, 289-304
 |  Abstract »  |  PDF »

Dopamine Receptor Transcript Expression in Striatum and Prefrontal and Occipital Cortex: Focal Abnormalities in Orbitofrontal Cortex in Schizophrenia.

J. H. Meador-Woodruff, V. Haroutunian, P. Powchik, M. Davidson, K. L. Davis, and S. J. Watson (1997)
Arch Gen Psychiatry 54, 1089-1095
 |  Abstract »  |  PDF »

Loss of haloperidol induced gene expression and catalepsy in protein kinase A-deficient mice.

M. R. Adams, E. P. Brandon, E. H. Chartoff, R. L. Idzerda, D. M. Dorsa, and G. S. McKnight (1997)
PNAS 94, 12157-12161
 |  Abstract »  |  Full Text »  |  PDF »

Effects of antipsychotic medication on electromyographic responses to transcranial magnetic stimulation of the motor cortex in schizophrenia.

N. J Davey, B. K Puri, H. S Lewis, S. W Lewis, and P. H Ellaway (1997)
J. Neurol. Neurosurg. Psychiatry 63, 468-473
 |  Abstract »  |  Full Text »  |  PDF »

PNU-96415E, a Potential Antipsychotic Agent with Clozapine-Like Pharmacological Properties.

A. H. Tang, S. R. Franklin, C. S. Himes, M. W. Smith, and R. E. Tenbrink (1997)
J. Pharmacol. Exp. Ther. 281, 440-447
 |  Abstract »  |  Full Text »

Selective Action of Acute Systemic Clozapine on Acetylcholine Release in the Rat Prefrontal Cortex by Reference to the Nucleus Accumbens and Striatum.

M. A. Parada, L. Hernandez, M. P. De Parada, P. Rada, and E. Murzi (1997)
J. Pharmacol. Exp. Ther. 281, 582-588
 |  Abstract »  |  Full Text »

Dopamine Receptor Subtypes: Differential Regulation after 8 Months Treatment with Antipsychotic Drugs.

W. J. Florijn, F. I. Tarazi, and I. Creese (1997)
J. Pharmacol. Exp. Ther. 280, 561-569
 |  Abstract »  |  Full Text »

Deprivation State Switches the Neurobiological Substrates Mediating Opiate Reward in the Ventral Tegmental Area.

K. Nader and D. van der Kooy (1997)
J. Neurosci. 17, 383-390
 |  Abstract »  |  Full Text »  |  PDF »

Local and Distributed Effects of Apomorphine on Fronto-Temporal Function in Acute Unmedicated Schizophrenia.

P. C. Fletcher, C. D. Frith, P. M. Grasby, K. J. Friston, and R. J. Dolan (1996)
J. Neurosci. 16, 7055-7062
 |  Abstract »  |  Full Text »  |  PDF »

Schizophrenia.

J. M. Kane (1996)
N. Engl. J. Med. 334, 34-42
 |  Full Text »  |  PDF »

Regional differences in the effect of haloperidol and atypical neuroleptics on interstitial levels of DOPAC in the rat forebrain: an in vivo microdialysis study.

A. Fink-Jensen, L. Hansen, J. B. Hansen, and E. B. Nielsen (1996)
J Psychopharmacol 10, 119-125
 |  Abstract »  |  PDF »

Clozapine Treatment of Schizophrenia.

D. Pickar and J. K. Hsiao (1995)
JAMA 274, 981-983
 |  Abstract »  |  PDF »

Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine.

P. A. Rao, D. Pickar, P. V. Gejman, A. Ram, E. S. Gershon, and J. Gelernter (1994)
Arch Gen Psychiatry 51, 912-917
 |  Abstract »  |  PDF »

Assessing the Validity of an Animal Model of Deficient Sensorimotor Gating in Schizophrenic Patients.

N. R. Swerdlow, D. L. Braff, N. Taaid, and M. A. Geyer (1994)
Arch Gen Psychiatry 51, 139-154
 |  Abstract »  |  PDF »

Schizophrenia as a Brain Disease: The Dopamine Receptor Story.

P. Seeman (1993)
Arch Neurol 50, 1093-1095
 |  Abstract »  |  PDF »

Effect of Neuroleptic Medication on Cerebrospinal Fluid Monoamine Metabolite Concentrations in Schizophrenia: Serotonin-Dopamine Interactions as a Target for Treatment.

R. S. Kahn, M. Davidson, P. Knott, R. G. Stern, S. Apter, and K. L. Davis (1993)
Arch Gen Psychiatry 50, 599-605
 |  Abstract »  |  PDF »

Monoamine Neurotransmitter Interactions in Drug-Free and Neuroleptic-Treated Schizophrenics.

K. H. John, C. Jean, J. J. Bartko, A. R. Doran, P. E. Konicki, W. z. Potter, and D. Pickar (1993)
Arch Gen Psychiatry 50, 606-614
 |  Abstract »  |  PDF »

Exclusion of Linkage Between Schizophrenia and the D2 Dopamine Receptor Gene Region of Chromosome 11q in 112 Irish Multiplex Families.

Su Ying, J. Burke, F. A. O'Neill, B. Murphy, L. Nie, B. Kipps, J. Bray, R. Shinkwin, M. N. Nuallain, C. J. MacLean, et al. (1993)
Arch Gen Psychiatry 50, 205-211
 |  Abstract »  |  PDF »

A Linkage Study of Chromosome 11q in Schizophrenia.

Z. W. Wang, D. Black, N. C. Andreasen, and R. R. Crowe (1993)
Arch Gen Psychiatry 50, 212-216
 |  Abstract »  |  PDF »

Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine: Relation to Extrapyramidal Side Effects.

L. Farde, A.-L. Nordstrom, F.-A. Wiesel, S. Pauli, C. Halldin, and G. Sedvall (1992)
Arch Gen Psychiatry 49, 538-544
 |  Abstract »  |  PDF »

Clinical and Biologic Response to Clozapine in Patients With Schizophrenia: Crossover Comparison With Fluphenazine.

D. Pickar, R. R. Owen, R. E. Litman, P. E. Konicki, R. Gutierrez, and M. H. Rapaport (1992)
Arch Gen Psychiatry 49, 345-353
 |  Abstract »  |  PDF »

Extending neurotransmitter hypotheses of neuroleptic action and schizophrenia beyond cell-surface receptors. The phosphoinositide signalling system provides a link between receptors and intracellular calcium.

M.A. Essali and S.R. Hirsch (1992)
J Psychopharmacol 6, 453-461
 |  PDF »

No Linkage Between D2 Dopamine Receptor Gene Region and Schizophrenia.

H. W. Moises, J. Gelernter, L. A. Giuffra, V. Zarcone, L. Wetterberg, O. Civelli, K. K. Kidd, L. L. Cavalli-Sforza, D. K. Grandy, J. L. Kennedy, et al. (1991)
Arch Gen Psychiatry 48, 643-647
 |  Abstract »  |  PDF »

Chronic Low-Dose MPTP in Nonhuman Primates: A Possible Model for Attention Deficit Disorder.

D. P. Roeltgen and J. S. Schneider (1991)
J Child Neurol 6, S82-S89
 |  Abstract »  |  PDF »

Circadian Variation of Plasma Homovanillic Acid Levels Is Attentuated by Fluphenazine in Patients With Schizophrenia.

A. R. Doran, R. Labarca, O. M. Wolkowitz, A. Roy, P. Douillet, and D. Pickar (1990)
Arch Gen Psychiatry 47, 558-563
 |  Abstract »  |  PDF »

D2 Dopamine Receptors in Neuroleptic-Naive Schizophrenic Patients: A Positron Emission Tomography Study With [11C]Raclopride.

L. Farde, F.-A. Wiesel, S. Stone-Elander, C. Halldin, A.-L. Nordstrom, H. Hall, and G. Sedvall (1990)
Arch Gen Psychiatry 47, 213-219
 |  Abstract »  |  PDF »

Sensorimotor Gating and Schizophrenia: Human and Animal Model Studies.

D. L. Braff and M. A. Geyer (1990)
Arch Gen Psychiatry 47, 181-188
 |  Abstract »  |  PDF »

Early psychopharmacology and the rise of modern brain research.

A. Carlsson (1990)
J Psychopharmacol 4, 120-126
 |  PDF »

Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine.

J. Kane, G. Honigfeld, J. Singer, and H. Meltzer (1988)
Arch Gen Psychiatry 45, 789-796
 |  Abstract »  |  PDF »

Plasma 3-Methoxy-4-Hydroxyphenylglycol Changes Associated With Clinical State and Schizophrenic Subtype.

G. N. Ko, D. C. Jimerson, R. J. Wyatt, and L. B. Bigelow (1988)
Arch Gen Psychiatry 45, 842-846
 |  Abstract »  |  PDF »

Brain imaging: applications in psychiatry.

N. Andreasen (1988)
Science 239, 1381-1388
 |  Abstract »  |  PDF »

Central D2-Dopamine Receptor Occupancy in Schizophrenic Patients Treated With Antipsychotic Drugs.

L. Farde, F.-A. Wiesel, C. Halldin, and G. Sedvall (1988)
Arch Gen Psychiatry 45, 71-76
 |  Abstract »  |  PDF »

Preliminary Evidence of Reduced Combined Output of Dopamine and Its Metabolites in Chronic Schizophrenia.

F. Karoum, C. N. Karson, L. B. Bigelow, W. B. Lawson, and R. J. Wyatt (1987)
Arch Gen Psychiatry 44, 604-607
 |  Abstract »  |  PDF »

To Advertise   |   Find Products